NCT01927120View on ClinicalTrials.gov

In Vivo Treg Expansion and Graft-Versus-Host Disease Prophylaxis

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 25, 2014

Primary Completion Date

August 25, 2016

Study Completion Date

March 9, 2017

Conditions
Graft-Versus-Host-Disease
Interventions
DRUG

IL-2

A subcutaneous injection will be administered 3 times a week (separated by at least 1 day between injections), from day 0 to +90 (+/- 7 days).

DRUG

Tacrolimus

Will be administered at 0.01 mg/kg/day (based on ideal body weight) continuous IV infusion or equivalent oral dosing starting on day -3

DRUG

Sirolimus

Orally on day -1. The dose for loading is 12 mg by mouth (PO)

Trial Locations (1)

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

All Listed Sponsors
lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER

NCT01927120 - In Vivo Treg Expansion and Graft-Versus-Host Disease Prophylaxis | Biotech Hunter | Biotech Hunter